Investment Rating - The report recommends an "Overweight" rating for solid-state batteries, innovative drugs, and new consumption sectors, while suggesting a "Neutral+" rating for humanoid robots and AI applications [5][10][21]. Core Insights - The report highlights a focus on solid-state batteries, innovative drugs, and new consumption as key investment themes, indicating a positive outlook for these sectors [5][10]. - The report notes that the overall emerging industry is showing a strong fundamental outlook with a neutral technical perspective, suggesting potential for growth despite recent fluctuations [16]. Summary by Relevant Sections Investment Themes - **Solid-State Batteries**: Rated "Overweight" with a strong technical outlook, indicating a recovery from a low position. The industry is moving towards commercialization with significant developments from companies like Geely [5][10]. - **Innovative Drugs**: Also rated "Overweight", with a stable outlook as the National Medical Products Administration has approved multiple innovative drugs, enhancing market confidence [5][10]. - **New Consumption**: Rated "Overweight", with initiatives in Beijing to promote new consumption landmarks, indicating a supportive environment for growth [5][10]. - **Humanoid Robots**: Rated "Neutral+", with a moderate technical outlook. The sector is experiencing a transition from prototypes to mass production, which could enhance market opportunities [5][10]. - **AI Applications**: Rated "Neutral+", with signs of recovery. The commercialization of AI applications is seen as a turning point, with significant investments from major companies [5][10]. Market Trends - The report indicates that the overall emerging industry has returned to below the mean plus two standard deviations, with moderate rotation intensity and average crowding levels, suggesting a potential for rebound in profitability expectations [16][18]. - Recent events, such as the launch of new products and approvals in the innovative drug sector, are expected to drive growth and investor interest [10][11].

医药生物 行 业 研 究 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-02 2025-06 2025-10 医药生物 沪深300 相关研究报告 《原料药行业价格更新—行业周报》 -2026.1.25 《业绩为王，继续重点推荐创新药产 业链板块性机会 — 行 业 周 报 》 -2026.1.18 | 余汝意（分析师） | 刘艺（联系人） | | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | liuyi1@kysec.cn 证书编号：S0790124070022 中国临床 CRO 行业进入"复苏+稳健增长"新阶段，供需结构持续改善 中国创新药产业已完成从十年前的"离岸外包服务模式"到如今"全球创新资产的 贡献者"的跃迁。临床 CRO 行业在经历 2017–2019 年成长期、2020–2022 年高景气 扩张及 2023–2024 年理性回调后，正进入新一轮复苏与稳定增长 ...

医药周报 20260130 从 JPM 大会挖掘 FIC 靶点三期数据验证节点 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从 JP Morgan 大会看 2026 MNC 密集验证新靶点 风险提示：1）医保、集采政策导致价格不及预期；2）临床进度或上市时间不及预期；3）行业竞争 格局的不确定性；4）地缘政治风险；5）下游投融资及需求复苏不及预期。 2026 年 02 月 01 日 推荐 维持评级 [Table_Author] | 分析师 张金洋 | | --- | | 执业证书： S0590525120012 | | 邮箱： zhangjinyang@glms.com.cn | | 分析师 胡偌碧 | | 执业证书： S0590525120011 | | 邮箱： huruobi@glms.com.cn | | 分析师 王彦迪 | | 执业证书： S0590525120015 | | 邮箱： wangyandi@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 医药 沪深300 相关研究 本公司具备证券投资咨询业务资格，请务 ...

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical industry [3] Core Insights - The report highlights the focus on innovation and internationalization within the pharmaceutical industry, with an emphasis on the development of innovative drugs and the exploration of new technological avenues [9][41] - The report suggests a dual investment strategy: one focusing on the rotation of technological innovation from 0 to 1 and the other on value recovery, emphasizing stocks with reasonable valuations and performance growth catalysts [9] - Key investment opportunities are identified in the CRO sector, with specific companies recommended for attention, including Tigermed, Baioo, and WuXi AppTec [9] Summary by Sections 1. Insights from JP Morgan Conference - The report discusses several new therapeutic targets presented at the JP Morgan conference, including Lp(a) siRNA therapy, FXI monoclonal antibodies, and TL1A monoclonal antibodies, all expected to yield phase III data in 2026 [12][18][22][34] - Notably, the Lp(a) siRNA drug Pelacarsen aims to reduce cardiovascular risks associated with Lp(a) levels through a novel mechanism [12][15] - FXI monoclonal antibodies are being developed for stroke prevention in atrial fibrillation patients, with promising data expected in 2026 [18][20] - TL1A monoclonal antibodies are being explored for ulcerative colitis, with data readouts anticipated in 2026 [22] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index experienced a week-over-week decline of 3.31%, underperforming both the ChiNext and CSI 300 indices [41] - The total trading volume for pharmaceuticals was 685.97 billion yuan, accounting for 4.52% of the total market, which is below the historical average of 7.10% [62] - The report notes that the pharmaceutical sector's valuation is currently below the historical average, with a PE ratio of 29.40, indicating a relative undervaluation [58] 3. Individual Stock Performance - The report lists the top-performing stocks for the week, including Cap Bio and Hualan Biological, while highlighting underperformers such as *ST Sailong and Hexin Instruments [66] - Monthly performance rankings show significant gains for stocks like Hongbo Pharmaceutical and Baolait, while others like Hezhong China faced substantial declines [66]

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it highlights a positive outlook for growth and innovation in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report emphasizes the transition from a capital-driven to a value-driven model in the surgical robot sector, indicating a shift towards more sustainable growth and clinical applications [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for domestic products, with orthopedic surgical robots leading in the number of approvals [30]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with notable products like the first remote surgical robot approved in China [16][19]. - The report highlights the introduction of AI-assisted surgical robots that enhance precision and efficiency in surgeries, marking a significant technological leap in the industry [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The report notes that the establishment of a clear payment system is crucial for the adoption of surgical robots in hospitals, as high costs and long return periods can deter procurement [27]. Market Segmentation - The orthopedic surgical robot segment dominates the market, accounting for 50% of the NMPA approvals from 2014 to 2024, with a strong growth trajectory expected in this area [30]. - The report identifies the laparoscopic surgical robot and orthopedic surgical robot as the two largest segments in the market, with significant potential for expansion in emerging fields [41]. Future Outlook - The report projects substantial growth in the surgical robot market, with expectations for increased penetration rates and market size driven by technological advancements and policy support [44]. - The anticipated CAGR for the laparoscopic surgical robot market from 2024 to 2033 is estimated at 30.4%, indicating robust future demand [44].

Core Viewpoint - The Chinese surgical robot industry is entering a rapid development phase, driven by policy support, capital investment, and technological advancements, with significant progress in various fields such as orthopedics and neurosurgery [13][21]. Market Overview - The CITIC Medical Index fell by 3.33% this week, underperforming the CSI 300 Index by 3.41 percentage points, ranking 22nd among 30 primary industries [8]. - The top ten stocks by growth this week included Cap Bio, Hualan Biological, and Dezheng Health, while the biggest losers were *ST Sailong and Vcare Pharmaceuticals [8]. Industry and Company Events - The surgical robot market is characterized by a shift from capital-driven to value-driven development, with increasing applications in remote surgery and AI-assisted decision-making [13][21]. - The NMPA has accelerated the approval of surgical robots, with orthopedic surgical robots accounting for 50% of the approved products from 2014 to 2024, maintaining the highest share [22]. Investment Themes - The innovative drug sector is transitioning from quantity to quality, emphasizing differentiated products and internationalization by 2025 [11]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment, with ongoing updates in home medical devices supported by subsidies [11]. - The CXO and life sciences services are expected to see a rebound in investment, with a focus on high-profit elasticity companies as the industry matures [11]. Technological Progress - Remote operation, miniaturization, and AI assistance are key trends in the surgical robot sector, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [17][19]. - The first AI-assisted orthopedic surgical robot, ROPA HIP, has been approved, showcasing advancements in surgical simulation technology [17]. Regulatory Developments - The National Medical Insurance Administration (NMPA) has established a pricing system for surgical robots, which is expected to enhance the industry's growth by clarifying reimbursement standards [21]. - The introduction of a legal and clear pricing project for surgical robots is anticipated to provide institutional support for innovation and development in the industry [21]. Sales and Market Dynamics - The sales volume of surgical robots in China reached 332 units in the first 11 months of 2025, reflecting a 3.75% year-on-year increase, while sales revenue decreased by 0.87% [27]. - The orthopedic surgical robot segment showed a significant growth of 17.81% in volume and 21.62% in revenue, indicating a robust demand in specialized fields [27]. Market Segmentation - The market for surgical robots is dominated by laparoscopic and orthopedic surgical robots, which accounted for 42% and 32% of the market share, respectively, in 2024 [25]. - Emerging fields such as vascular surgery robots are expected to present substantial market potential as the industry evolves [27].

1月30日晚间，百利天恒发布业绩预告称，预计2025年实现归属净利润为-11亿元左右，同比由盈转亏。 对于业绩亏损，百利天恒表示，去年为加快推进产品管线的研发进度，巩固产品管线的领先优势，早日实现产品上市以惠及患者，公司持续加大研发投 入，导致研发投入同比增幅较大。 公司还表示，去年公司与百时美施贵宝(BMS)就iza-bren的合作顺利推进，全球II/III期关键注册临床试验IZABRIGHT-Breast01里程碑达成，并收到第一笔 2.5亿美元里程碑付款。上年同期，公司收到BMS就iza-bren合作协议的8亿美元不可撤销、不可抵扣的首付款，公司相应确认相关知识产权收入。去年收 入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收入。 截至去年末，公司共有17款创新药处于临床试验阶段(其中6款创新药处于全球临床试验)。公司正在全球范围内开展100余项创新药临床试验。核心产品 iza-bren(EGFR×HER3双抗ADC)两个适应症——用于治疗局部晚期或转移性鼻咽癌、用于治疗复发性或转移性食管鳞癌——的上市申请(NDA)已获得国家 药监局药品审评中心受理且被纳入优先审评 ...

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

孟科含 Kehan Meng 聂照亿 Zhaoyi Nie kh.meng@htisec.com john.zy.nie@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康在创新多肽分子发现和长效递 送产品的开发领域开展全面战略合作。 ...

[Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment 孟科含 Kehan Meng 聂照亿 Zhaoyi Nie 3）双方还将依托该等平台就另外四个新增项目开展合作。 kh.meng@htisec.com john.zy.nie@htisec.com 交易对价 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康 ...